The present invention provides a novel compound represented by a general formula (1) as shown below, which has a glucokinase-activating action in the liver and pancreatic β-cells and which is useful as an agent for preventing and/or treating diseases caused by hyperglycemia, such as diabetes.A spiroindoline compound represented by the general formula (1), or a salt thereof, or a solvate of the compound or the salt:[wherein ring A represents a nitrogen-containing 5-10 membered heteroaryl group；R1 and R2, which are the same or different, each represent a hydrogen atom, a halogen atom, a halo C1-6 alkyl group, a C6-10 aryl group, a cyano group, a C1-6 alkyl group optionally having a substituent, a C2-6 alkenyl group optionally having a substituent, etc.； R3 represents a hydrogen atom, a C1-6 alkyl group optionally having a substituent, etc.； and R4 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally having a substituent, etc.]
